Your Trusted Brand for Over 35 Years

Polycystic Ovary Syndrome (PCOS) References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Azziz R, Woods KS, Reyna R, et al. (June 2004). "The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population". Journal of Clinical Endocrinology & Metabolism 89 (6): 2745–9.
  2. Azziz R, Carmina E, Dewailly D et al. Androgen Excess Society: Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J ClinEndocrinolMetab 2006, 91:4237-4245.
  3. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug;16(4):347-63.
  4. McCartney CR, Bellows AB, Gingrich MB, et al. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J PhysiolEndocrinolMetab. 2004 Jun;286(6):E902-8.
  5. Diamanti-Kandarakis E et al. Pathophysiology and types of dyslipidemia in PCOS. Trends in Endocrinology & Metabolism. 2007 September; 18 (7): 280–285.
  6. Sasaki A, Emi Y, Matsuda M et al. Increased arterial stiffness in mildly-hypertensive women with polycystic ovary syndrome. J ObstetGynaecol Res. 2011 Feb 11. doi: 10.1111/j.1447-0756.2010.01375.x.
  7. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Reviews in Molecular Medicine 2008 10 e3 (Review).
  8. Drosdzol A, Skrzypulec V, Mazur B, Pawlińska-Chmara R. Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome. Folia HistochemCytobiol. 2007;45 Suppl1:S93-7.
  9. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 Jun 30;8:41.
  10. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009 Sep;19(3):398-405.
  11. Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. ClinEndocrinol (Oxf). 2011 Apr;74(4):424-433.
  12. Ma YM, Li R, Qiao J, Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J (Engl). 2010 Aug;123(16):2185-9.
  13. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. DermatolTher. 2006 Jul-Aug;19(4):210-23.
  14. Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online. 2004 Jun;8(6):644-8.
  15. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res ClinObstetGynaecol. 2004 Oct;18(5):755-71.
  16. Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF. Obesity and the polycystic ovary syndrome. Minerva Endocrinol. 2007 Sep;32(3):129-40.
  17. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, GarrapaGG, Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004 May;27(5):424-9.
  18. Pasquali R, Gambineri A.Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol. 2006 Jun;154(6):763-75.
  19. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004 Feb;56(1):41-51.
  20. Higgins SP, Freemark M, Prose NS. Acanthosisnigricans: a practical approach to evaluation and management. Dermatol Online J. 2008 Sep 15;14(9):2.
  21. Artini PG, Di Berardino OM, Simi G, Best methods for identification and treatment of PCOS. Minerva Ginecol. 2010 Feb;62(1):33-48.
  22. Shi Y, Guo M, Yan J et al. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. NeuroEndocrinolLett. 2007 Dec;28(6):807-10.
  23. Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008 Apr;23(4):952-7.
  24. Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J ClinEndocrinolMetab. 2010 Sep;95(9):4399-405.
  25. van Houten EL, Themmen AP, Visser JA. Anti-Müllerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010 May;71(3):191-7.
  26. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010 May;139(5):825-33.
  27. Chang PL, Lindheim SR, Lowre C,. Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing. J ClinEndocrinolMetab. 2000; 85(3): 995-1000
  28. Guzick DS. Polycystic ovary syndrome. ObstetGynecol 2004;103:181-193.
  29. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. ClinEndocrinol (Oxf) 2004;60:1-17.
  30. Carmina E. Diagnosing PCOS in women who menstruate regularly. ContempObstetGynecol 2003;53-64.
  31. Jakubowski L. [Genetic aspects of polycystic ovary syndrome]. Endokrynol Pol. 2005 May-Jun;56(3):285-93.
  32. Diamanti-Kandarakis, E, et al. The role of genes and environment in the etiology of PCOS. Endocrine. 2006 August; 30 (1): 19-26.
  33. Bremer AA and Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. FertilSteril. 2008 May;89(5):1039-48.
  34. Wood JR, Nelson VL, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem. 2003 Jul 18;278(29):26380-90.
  35. Villa J, Pratley RE. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. CurrDiab Rep. 2011 Mar 19. [Epub ahead of print]
  36. Witchel SF. Puberty and polycystic ovary syndrome. Mol Cell Endocrinol. 2006 Jul 25;254-255:146-53.
  37. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. FertilSteril. 2011 Mar 1;95(3):1048-58.e1-2.
  38. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J. 2004 Apr;51(2):165-9.
  39. Petríková J, Lazúrová I. Polycystic ovary syndrome and autoimmune diseases. VnitrLek. 2010 May;56(5):414-7.
  40. Hernández I, Parra A, Méndez I, et al. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome. Arch Med Res. 2000 Mar-Apr;31(2):216-22.
  41. Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. GynakolGeburtshilflicheRundsch. 2008;48(1):9-15.
  42. Kopera D, Wehr E, Obermayer-Pietsch B. Endocrinology of hirsutism. Int J Trichology. 2010 Jan;2(1):30-5.
  43. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010 Nov-Dec;8(6):328-32; quiz 333.
  44. Polyzos NP, Tzioras S, Badaway AM et al. Aromatase inhibitors for female infertility: a systemic review of the literature. Reprod Biomed Online 2009 Oct;19(4):456-71.
  45. Fica S, Albu A, Constantin M, Dobri GA. Insulin resistance and fertility in polycystic ovary syndrome. J Med Life. 2008 Oct-Dec;1(4):415-22.
  46. Abu Hashim H, Anwar K, El-Fatah RA. N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. J Womens Health (Larchmt). 2010 November; 19(11): 2043-8.
  47. Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2000;(4):CD000410.
  48. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online. 2009 Oct;19(4):456-71.
  49. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.FertilSteril. 2001 Feb;75(2):305-9.
  50. Cianci A, De Leo V. Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives. Minerva Ginecol. 2007 Aug;59(4):415-25.
  51. National Institute for Health and Clinical Excellence. 11 Clinical guideline 11 : Fertility: assessment and treatment for people with fertility problems . London, 2004.
  52. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J ClinEndocrinolMetab. 2001 Apr;86(4):1626-32.
  53. Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The Metabolic Status Modulates the Effect of Metformin on the Antimullerian Hormone-Androgens-Insulin Interplay in Obese Women with Polycystic Ovary Syndrome. J ClinEndocrinolMetab. 2011 Feb 9. [Epub ahead of print]
  54. Yasmin E, Glanville J, Barth J, Balen AH. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. Eur J ObstetGynecolReprod Biol. 2011 Jan 27. [Epub ahead of print]
  55. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105(23):2696–2698.
  56. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011 Feb 8;3:25-35.
  57. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J ClinEndocrinolMetab. 2005;90(8):4593–4598.
  58. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858–2864.
  59. Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;(1):CD003053. Doi: 10.1002/14651858.CD003053.
  60. Palomba S et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010 Feb;33(2):246-51.
  61. Mastorakos G, Koliopoulos C, Deligeoroglou E et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertility and Sterility. 2006 February; 85(2): 420-427.
  62. Manning BD. Insulin signaling: inositol phosphates get into the Akt. Cell. 2010 Dec 10;143(6):861-3.
  63. Larner J et al. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010 Nov-Dec;16(11-12):543-52.
  64. Susuki S et al. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care. 1994 Dec;17(12):1465-8.
  65. Jung TS et al. Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients. Yonsei Med J. 2005 Aug 31;46(4):532-8.
  66. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism. 2008 Oct;57(10):1390-7.
  67. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. . Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. MetabSyndrRelatDisord. 2010 Apr;8(2):127-36.
  68. Nestler JE et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20.
  69. Luorno MJ et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. EndocrPract. 2002 Nov-Dec;8(6):417-23.
  70. Baillargeon JP, Iuorno MJ, Jakubowicz DJ,et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J ClinEndocrinolMetab. 2004 Jan;89(1):242-9.
  71. Costantino D et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.
  72. Genazzani AD, Lanzoni C, Ricchieri F, JasonniVM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. GynecolEndocrinol. 2008 Mar;24(3):139-44.
  73. Gerli S et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54.
  74. Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. GynecolEndocrinol. 2009 Aug;25(8):508-13.
  75. Papaleo E et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. GynecolEndocrinol. 2007 Dec;23(12):700-3.
  76. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J ObstetGynecolReprod Biol. 2009 Dec;147(2):120-3.
  77. Kang MJ, Kim JI, Yoon SY, Kim JC, Cha IJ. Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus. J Med Food. 2006 Summer; 9(2):182-6.
  78. Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol. 2000 August; 130(8): 1944–1948.
  79. Kim MJ, et al. Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Res Clin Prac. 2007;77(Suppl 1):S247-S251.
  80. Kim JI, et al. Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. EurJournClinNutr. 2005; 59: 456–458.
  81. Fulghesu, AM, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. FertilSteril. 2002 June; 77(6): 1128-1135.
  82. Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and lomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. FertilSteril. 2010 Sep;94(4):1405-9.
  83. Badawy A, State O, Abdelgawad S. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. ActaObstetGynecol Scand. 2007;86(2):218-22.
  84. Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. FertilSteril. 2005 Feb;83(2):367-70.
  85. Badaway, A, State O, El Gawad S et al. Plasma homocysteine and polycystic ovary syndrome: The missed link. Eur J ObstetGynecolReprod Biol. 2007 March; 131(1): 68-72.
  86. Rymarz A, Durlik M, Rydzewski. Intravenous administration of N-acetylcysteine reduces plasma total homocysteine levels in renal transplant recipients. Ann Transplant. 2009 Oct-Dec; 14(4): 5-9.
  87. Kauffman RP, Tullar PE, Nipp RD, Castracane VD. Serum magnesium concentrations and metabolic variables in polycystic ovary syndrome. ActaObstetGynecol Scand. 2011 Jan 4. doi: 10.1111/j.1600-0412.2010.01067.x. [Epub ahead of print]
  88. De Lourdes Lima, M, Cruz T, PousadaJC, Rodrigues LE, Barbosa K, Canguco V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998 May; 21: 682-86.
  89. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care. 2003 April; 26:1147-52.
  90. Mooren FC, Kruger K, Völker S, Golf W, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects – a double-blind, placebo-controlled, randomized trial. Diabetes, Obesity and Metabolism. 2011 March; 13 (3): 281-84.
  91. Lucidi RS, et al. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. FertilSteril. 2005 December; 84(6):1755-7.
  92. Pershadsingh HA. Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert OpinInvestig Drugs. 2007 Mar;16(3):291-302.
  93. Masharani U, Gjerde C, Evans JL, YoungrenJF, GoldfineID.Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010 Mar 1;4(2):359-64.
  94. Wehr EB et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011 Mar 9.
  95. Rashidi B et al. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol. 2009 Jun;48(2):142-7.
  96. Thys-Jacobs S, Donovan D, Papadopoulos A, et al. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids.1999 June; 64(6):430-5.
  97. Cussons AJ, et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J ClinEndocrinolMetab. 2009 October; 94(10):3842-8.
  98. Shultz TD, Bonorden WR, R. Seaman MS Wanda. Effect of short-term flaxseed consumption on lignan and sex hormone metabolism in men. Nutr Res. 1991 October; 11 (10): 1089-1100.
  99. Nowak DA, Snyder DC, Brown AJ, Demark-Wahnefried W. The Effect of Flaxseed Supplementation on Hormonal Levels Associated with Polycystic Ovarian Syndrome: A Case Study. Curr Top Nutraceutical Res. 2007; 5(4): 177–181.
  100. Broadhurst L, Polansky MM, Anderson, RA. Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. J Agric Food Chem. 2000 Mar; 48(3):849–52.
  101. Cao H, Graves DJ, Anderson RA. Cinnamon extract regulates glucose transporter and insulin-signaling gene expression in mouse adipocytes. Phytomedicine. 2010 Nov;17(13):1027-32.
  102. Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004 Jan 14;52(1):65-70
  103. Khan A et al. Cinnamon Improves Glucose and Lipids in People with Type 2 Diabetes. Diabetes Care. 2003; 26:3215-18.
  104. Wang JG, et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. FertilSteril. 2007 July; 88(1): 240-3. Epub 2007 Feb 12.
  105. Armamani D, et al. Licorice reduces serum testosterone in healthy women. Steroids. 2004 October-November; 69 (11-12): 763-766.
  106. Takahashi K, et al. Effect of a traditional herbal medicine (shakuyaku-kanzo-to) on testosterone secretion in patients with polycystic ovary syndrome detected by ultrasound. Nippon SankaFujinkaGakkaiZasshi. 1988 June; 40(6):789-92.
  107. Takeuchi T, Nishii O, Okamura T, Yaginuma T. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med. 1991;19(1):73-8.
  108. Armanini D et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J ObstetGynecolReprod Biol. 2007 Mar;131(1):61-7.
  109. Tsuneki H, Ishizuka M, Terasawa M, et al. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 2004 August; 26(4):18.
  110. Potenza MA, et al. GCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J PhysiolEndocrinolMetab. 2007 May; 292(5): E1378-87. Epub 2007 Jan 16.
  111. Venables MC, et al. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J ClinNutr. 2008 March; 87(3): 778-84.
  112. Wolfram S, Raederstorff D, Preller M, et al. Epigallocatechingallate supplementation alleviates diabetes in rodents. J Nutr. 2006 October;136(10): 2512-8.
  113. Fukino Y, et al. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J ClinNutr. 2008 August; 62(8): 953-60.
  114. Ivanov V, et al. Natural nutrient mixture effectively reduces collagen matrix contraction driven by human uterine smooth muscle cells. J ObstetGynaecol Res. 2006 February;32(1):23-31.
  115. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J ClinNutr 1999; 70:1040–5.
  116. Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010 Feb; 24(2):186-8.
  117. Prager N, Bicket K, French N, Marovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Alter Complement Med. 2002 April ;8(2): 143-152.
  118. Kiddy DS, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. ClinEndocrinol. 1992 January; 36(1):105-11.
  119. Berrino F, et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev. 2001 January; 10(1): 25-33.
  120. Douglas CC, et al. Role of diet in the treatment of polycystic ovary syndrome. FertilSteril. 2006 March; 85(3): 679-88.
  121. Marsh K, et al. The optimal diet for women with polycystic ovary syndrome? Br J Nutr. 2005 August; 94(2):154-65.